Heart Failure With Reduced Ejection Fraction
Conditions
Brief summary
A research study to evaluate the impact of a novel care pathway for patients diagnosed with Heart Failure within Chiltern CCG, supported by an integrated clinical patient record. Assessment of patient outcomes following implementation of Care4Today(R) Heart Failure Platform.
Detailed description
This is an exploratory study to evaluate the impact of the novel Care4Today HF platform on a set of outcomes including hospital admission rate (primary diagnosis), 30 days post discharge readmission rate, length of hospital stay for patients with HF (primary and secondary diagnosis), patient quality of life, and patient clinical metrics. The study design includes comparison of two parallel cohorts: one where patients will be managed via the Care4Today HF platform (active cohort) and a second, where patients will be managed as per existing standards of care (control cohort). Evaluation phase: The evaluation phase will be set up to assess the potential benefits of the Care4Today HF platform. This will be implemented across 10 GP practices who will be part of the active cohort, within the Chiltern CCG region. The outcomes for these patients will be compared with the outcomes of patients in the control cohort over a one year period. Patients pathway (for the active cohort): Once the diagnosis of HF is confirmed, a HF specialist project nurse will register the patient on the Care4Today platform and provide the patient with instructions on how to use the patient portal, where patients can input various clinical measures, communicate with HCPs and track their condition. Complex patients, and/or patients that are deteriorating are referred to the community HF specialist nurse team where they will be monitored and managed.
Interventions
OTHERCare4todayheart failure platform
Platform allowing patients to enter information about their health at home, namely weight and BP and medications
Sponsors
Janssen-Cilag Ltd.
Buckinghamshire Healthcare NHS Trust
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Two arms, one using the platform to help manage their heart failure and one standard of care.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults 18 years of age or older with the primary diagnosis of heart failure * Must have moderate to severe LVSD (ejection fraction \<= 40%) confirmed by an echocardiogram and/or other cardiac imaging
Exclusion criteria
* Patients with right heart failure as a consequence of respiratory disease * Patients with Heart Failure with preserved Ejection Fraction * Patients with significant learning disability, or severe mental health conditions * Patients with metabolic heart disease e.g. amyloid * Patients with severe non-operable valve disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hospital admissions | 12 months | number of hospital admissions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| all cause readmissions | 12 months | mean number of all cause readmissions |
| length of stay | 12 months | o Mean, median (SD) days of length of stay (for admissions with a primary and secondary diagnosis of HF) |
| weight change | 12 months | Mean (SD) change in weight |
| mean number of heart failure readmissions within 30 days of discharge | 30 days of discharge | mean number of heart failure readmissions within 30 days of discharge |
| Hospital Anxiety and Depression Scale score | 12 months | Mean change in Hospital Anxiety and Depression Scale (HADS) at the start and after 1 year the end of the study. Score on scale of 0-21, 0-7 = normal, 8-10 borderline, 11-21 abnormal. Higher score = worse outcome |
| QOL | 12 months | o Mean change in Quality of Life assessed by Minnesota Living with Heart Failure Questionnaire and EQ5D or EQVAS |
| Blood pressure | 12 months | o Proportion of patients achieving target for blood pressure (140/90mmHg or 130/80mmHg for patients with diabetes) at the end of the study |
Outcome results
None listed